|
ADMIRE
AMP579 Delivery for Myocardial Infarction Reduction
 |
Author(s) |
Kopecky SL, Midei MG, Kellett MA, Butler JF, Holland AE, Zannikos PN, Tipping DM, Gibbons RJ, Lee SW, Bell MR
|
 |
Title(s) |
Report of AMP579 Delivery for Myocardial Infarction Reduction (ADMIRE)
|
|
Reference(s) |
Circulation 1999;100 Suppl I:I-651
|
|
Disease |
AMI
|
|
Purpose |
To determine whether treatment with a mixed adenosine agonist (AMP579) reduces final MI size
|
|
Study design |
Randomised, double-blind, placebo-controlled
|
|
Follow-up |
120-216 h
|
|
Patients |
321 patients with acute ST-segment elevation, anterior or non-anterior MI, undergoing primary PTCA within 6 h of the onset of symptoms
|
|
Treatment regimen |
AMP579, 15, 30 or 60 µg/kg as a continuous infusion over 6 h, or placebo
|
|
Results |
The median final infarct size was 10% with no significant difference between the treatment and placebo groups. A trend towards a reduction in final infarct size was seen in anterior MI patients receiving higher doses of AMP579, 30 µg/kg (14.0%) and 60 µg/kg (13.5%), compared to placebo (18.3%). A trend towards increased myocardial salvage in the anterior MI group was also seen at baseline and at days 5-9
|
|
|
|
